Published in Free Radic Biol Med on December 16, 2013
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med (2015) 0.95
From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov (2016) 0.92
GSK-3β downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci Rep (2016) 0.83
Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis (2015) 0.82
The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med (2014) 0.81
An overview on the correlation of neurological disorders with cardiovascular disease. Saudi J Biol Sci (2014) 0.80
Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review. Br J Clin Pharmacol (2015) 0.77
DNA Demethylation Upregulated Nrf2 Expression in Alzheimer's Disease Cellular Model. Front Aging Neurosci (2016) 0.76
Dietary Intake of Nutrients and Lifestyle Affect the Risk of Mild Cognitive Impairment in the Chinese Elderly Population: A Cross-Sectional Study. Front Behav Neurosci (2016) 0.75
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS Genet (2017) 0.75
Administration of NaHS Attenuates Footshock-Induced Pathologies and Emotional and Cognitive Dysfunction in Triple Transgenic Alzheimer's Mice. Front Behav Neurosci (2015) 0.75
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. Sci Rep (2017) 0.75
The effect of Bacopa monnieri on gene expression levels in SH-SY5Y human neuroblastoma cells. PLoS One (2017) 0.75
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? Antioxidants (Basel) (2017) 0.75
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun (1997) 14.09
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev (1999) 13.43
Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A (2002) 8.01
Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol (2003) 6.91
Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J (1990) 6.23
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci (2003) 3.54
Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem (1999) 3.41
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
The many faces of tau. Neuron (2011) 2.89
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J (2006) 2.67
On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem (2004) 2.37
Judging a protein by more than its name: GSK-3. Sci STKE (2001) 2.27
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem (1997) 2.12
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res (1999) 1.92
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80
Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63
GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis (2006) 1.62
Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol (2007) 1.50
Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem (2004) 1.49
Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol (1996) 1.44
A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis (2009) 1.42
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett (1999) 1.23
Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther (2001) 1.19
Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med (2012) 1.18
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res (1988) 1.16
Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides (2000) 1.15
Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev (1998) 1.15
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci (2012) 1.13
Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res (2005) 1.08
Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience (2004) 1.06
Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides (2000) 1.05
From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis (2008) 1.04
Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res (2004) 1.04
Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun (2003) 1.03
Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis (2012) 0.94
In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases. Neurobiol Aging (2011) 0.93
Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology (2012) 0.91
Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM). Neurobiol Aging (2006) 0.88
Activation of Akt by lithium: pro-survival pathways in aging. Mech Ageing Dev (2009) 0.84
Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary ethanol drinking. Peptides (2005) 0.83
Making sense of therapeutics using antisense technology. Expert Opin Drug Discov (2011) 0.82
Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target? Int J Alzheimers Dis (2012) 0.81
AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs (2008) 0.80